cat no | io1067
A rapidly maturing, physiologically relevant, functional system for investigating the role of the APP London mutation in early-onset Alzheimer's disease (AD). This in vitro disease cell model recapitulates an increased ratio of amyloid beta peptides Aً›½42:40, as observed in AD.
ioGlutamatergic Neurons APP V717I/WT are opti‑ox deterministically programmed glutamatergic neurons carrying a genetically engineered heterozygous V717I mutation in the APP gene encoding amyloid precursor protein.
This disease model is part of an Alzheimer's disease panel of human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. A second clone for the APP V717I het mutation is available for scientists who wish to repeat their experiments in independent clones, please enquire. All disease models are genetically matched to the wild type control, ioGlutamatergic Neurons. Additional mutations in the AD panel include homozygous APP V717I , and heterozygous and homozygous APP KM670/671NL and PSEN1 M146L, alongside AD-relevant mutations in ioGABAergic Neurons and ioMicroglia.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@خقسا¶جتسئµ.
Disease related phenotype
Increased ratio of Aً›½42:40 peptides compared to the genetically matched control, measured by immunoassay.
Make True Comparisons
Pair the Alzheimer's disease model cells with the wild type glutamatergic neurons to investigate the impact of the APP missense mutation.
Quick
The disease model cells and genetically matched control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
Increased ratio of Aً›½42:40 seen in ioGlutamatergic Neurons APP V717I (London), as observed in Alzheimer’s disease
ioGlutamatergic Neurons APP V717I disease model cells show increased production of Aً›½38 and Aً›½42 peptides (involved in the amyloidogenic pathway), with no difference seen for Aً›½40 (A). This results in an increased ratio of Aً›½42:40 and no change in the Aً›½42:38 ratio (B).
ioGlutamatergic Neurons APP V717I/WT express neuron-specific markers comparably to the wild type control
Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons APP V717I/WT (CL35) compared to the genetically matched control. 100X magnification.
ioGlutamatergic Neurons APP V717I/WT form structural neuronal networks by day 11
ioGlutamatergic Neurons APP V717I/WT mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.
ioGlutamatergic Neurons APP V717I/WT demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming
Gene expression analysis demonstrates that ioGlutamatergic Neurons APP V717I/WT and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, while robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.
Disease-related APP is expressed in ioGlutamatergic Neurons APP V717I/WT following deterministic programming
RT-qPCR analysis demonstrates expression of the APP gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons APP V717I/WT at day 11 post-revival. Data normalised to HMBS, n=2 replicates.
ioGlutamatergic Neurons APP V717I/WT are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.
The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.
Starting material
Human iPSC line
Karyotype
Normal (46, XY)
Seeding compatibility
6, 12, 24, 96 & 384 well plates
Shipping info
Dry ice
Donor
Caucasian adult male, age 55-60 years old (skin fibroblast)
Vial size
Small: >1 x 10âپ¶ viable cells
Quality control
Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)
Differentiation method
opti-ox deterministic cell programming
Recommended seeding density
30,000 cells/cmآ²
User storage
LN2 or -150آ°C
Format
Cryopreserved cells
Genetic modification
Heterozygous V717I missense mutation in the APP gene
Applications
Alzheimer's disease research
Drug discovery and development
Disease modelling
Available clones
io1067 | APP V717I/WT (CL35)
io1068 | APP V717I/WT (CL58)
Product use
ioCells are for research use only
خقسا¶جتسئµ
V11
خقسا¶جتسئµ
2024
Professor Deepak Srivastava
Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders
King’s College London
Emmanouil Metzakopian | Vice President, Research and Development | خقسا¶جتسئµ
Javier Conde-Vancells | Director Product Management | خقسا¶جتسئµ
Chakraborty et al
Nature Communications
2023
Featuring ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | خقسا¶جتسئµ
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | خقسا¶جتسئµ
Oosterveen, et al
خقسا¶جتسئµ & Charles River Laboratories
2023
Qiaojin Lin et al
The EMBO Journal
2023
Featuring opti-ox powered hiPSC-derived glutamatergic neurons with constitutive expression of Cas9
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Further your disease research by pairing our wild type cells with isogenic disease models.